PE20121534A1 - Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo - Google Patents

Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo

Info

Publication number
PE20121534A1
PE20121534A1 PE2012000428A PE2012000428A PE20121534A1 PE 20121534 A1 PE20121534 A1 PE 20121534A1 PE 2012000428 A PE2012000428 A PE 2012000428A PE 2012000428 A PE2012000428 A PE 2012000428A PE 20121534 A1 PE20121534 A1 PE 20121534A1
Authority
PE
Peru
Prior art keywords
maitansinoids
antibody
conjugate
new
cdr
Prior art date
Application number
PE2012000428A
Other languages
English (en)
Inventor
Herve Bouchard
Alain Commercon
Claudia Fromond
Vincent Mikol
Fabienne Parker
Ingrid Sassoon
Daniel Tavares
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41698152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121534(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20121534A1 publication Critical patent/PE20121534A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I): DONDE ALK ES UN GRUPO ALQUILENO(C1-C6); X1 Y X2 SON INDEPENDIENTEMENTE -CH=CH-, -CO-, -CONR-, -NRCO-, ENTRE OTROS; Zb ES UN ENLACE SENCILLO Y Rb ES HAL O Zb ES UN ENLACE SENCILLO, -O-, O -NH- Y Rb ES H O UN GRUPO ALQUILO(C1-C6), ARILO, CICLOALQUILO(C3-C7), ENTRE OTROS; j ES 1 CUANDO X2 ES -CH=CH- Y 2 CUANDO X2 NO ES -CH=CH-; i ES UN ENTERO DE 1 A 40. REFERIDO TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE UN CONJUGADO, DONDE EL ANTICUERPO DE DICHO CONJUGADO ES UN ANTICUERPO QUE SE UNE AL EPITOPO QUE SE UNE A UN RECEPTOR EphA2 Y COMPRENDE AL MENOS UNA CADENA PESADA CON 3 CDR CON SECUENCIAS DE AMINOACIDOS DE SEQ ID NOS: 1, 2 Y 3, Y CADENA LIGERA CON 3 CDR CON SECUENCIA DE AMINOACIDOS DE SEQ ID NOS: 4, 5 Y 6. DICHO COMPUESTO Y CONJUGADO SON UTILES COMO AGENTES CANCERIGENOS
PE2012000428A 2009-10-02 2010-09-30 Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo PE20121534A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09305939 2009-10-02

Publications (1)

Publication Number Publication Date
PE20121534A1 true PE20121534A1 (es) 2012-12-03

Family

ID=41698152

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000428A PE20121534A1 (es) 2009-10-02 2010-09-30 Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo

Country Status (24)

Country Link
US (1) US20120276124A1 (es)
EP (1) EP2483279A1 (es)
JP (1) JP2013506653A (es)
KR (1) KR20120091166A (es)
CN (1) CN102741260A (es)
AR (1) AR078471A1 (es)
AU (1) AU2010302247A1 (es)
BR (1) BR112012007305A2 (es)
CA (1) CA2774916A1 (es)
CL (1) CL2012000820A1 (es)
CR (1) CR20120147A (es)
EA (1) EA201270473A1 (es)
EC (1) ECSP12011756A (es)
IL (1) IL218740A0 (es)
MA (1) MA33702B1 (es)
MX (1) MX2012003998A (es)
NI (1) NI201200051A (es)
NZ (1) NZ599045A (es)
PE (1) PE20121534A1 (es)
TN (1) TN2012000115A1 (es)
TW (1) TW201117814A (es)
UY (1) UY32913A (es)
WO (1) WO2011039721A1 (es)
ZA (1) ZA201202328B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
UY32914A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
RU2018122734A (ru) 2012-10-04 2018-07-24 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент-цитотоксический агент
NO2789793T3 (es) * 2012-10-24 2018-01-27
MY169147A (en) * 2012-10-24 2019-02-18 Polytherics Ltd Drug-protein conjugates
CN104650113A (zh) * 2012-12-21 2015-05-27 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
BR112015022585B1 (pt) 2013-03-15 2023-04-04 Regeneron Pharmaceuticals, Inc Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos
US20160143914A1 (en) * 2013-06-13 2016-05-26 Emory University Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof
AU2014311361B2 (en) 2013-08-26 2018-11-29 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
CN103483357B (zh) * 2013-10-12 2015-11-18 齐鲁制药有限公司 一种抗体-美登素偶联物的中间体新晶型及其制备方法
AU2014354643B2 (en) 2013-11-27 2020-03-05 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9562059B2 (en) * 2013-12-02 2017-02-07 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
KR20170088905A (ko) 2014-11-19 2017-08-02 이뮤노젠 아이엔씨 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정
CN106267225B (zh) 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
EP3308801A4 (en) 2015-06-09 2019-02-27 XDCExplorer (Shanghai) Co., Ltd. ANTIBODY-MEDICINAL CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
JP6638970B2 (ja) * 2015-06-30 2020-02-05 株式会社 東北テクノアーチ ヘテロ型単分散ポリエチレングリコール、ヘテロ型単分散ポリエチレングリコール製造用中間体の製造方法
MA43094B1 (fr) 2016-01-25 2020-10-28 Regeneron Pharma Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation
RU2018130108A (ru) 2016-02-05 2020-03-06 Иммуноджен, Инк. Эффективный способ получения конъюгатов связывающийся с клеткой агент цитотоксический агент
US10195283B2 (en) * 2016-03-18 2019-02-05 R.P. Scherer Technologies, Llc Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate
CN107652219B (zh) 2017-08-14 2021-06-08 上海新理念生物医药科技有限公司 四马来酰亚胺型连接子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
ES2539627T3 (es) 2002-11-07 2015-07-02 Immunogen, Inc. Anticuerpos anti-CD33 y método para el tratamiento de leucemia mieloide aguda usando los mismos
EP2633856A3 (en) * 2003-05-09 2014-01-01 The Trustees of The University of Pennsylvania ATP citrate lyase inhibitors for treating cancer
SI1651162T1 (sl) 2003-05-20 2016-02-29 Immunogen, Inc. Izboljšani citotoksični agenti, ki vsebujejo nove majtanzinoide
EA014640B1 (ru) 2003-07-21 2010-12-30 Иммьюноджен, Инк. Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
ATE535529T1 (de) 2005-08-09 2011-12-15 Millennium Pharm Inc Verfahren zur acylierung von maytansinol mit chiralen aminosäuren
CA2620343C (en) * 2005-08-24 2013-01-08 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
AU2007274738B2 (en) * 2006-07-18 2013-11-28 Sanofi-Aventis Antagonist antibody against EphA2 for the treatment of cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
KR20100137585A (ko) * 2008-04-30 2010-12-30 이뮤노젠 아이엔씨 강력한 복합체 및 친수성 링커
UY32914A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2

Also Published As

Publication number Publication date
NI201200051A (es) 2012-08-09
CL2012000820A1 (es) 2012-08-31
CA2774916A1 (en) 2011-04-07
UY32913A (es) 2011-04-29
NZ599045A (en) 2013-09-27
US20120276124A1 (en) 2012-11-01
MA33702B1 (fr) 2012-10-01
WO2011039721A1 (en) 2011-04-07
IL218740A0 (en) 2012-06-28
JP2013506653A (ja) 2013-02-28
BR112012007305A2 (pt) 2016-12-06
TN2012000115A1 (en) 2013-09-19
CR20120147A (es) 2012-06-01
AU2010302247A1 (en) 2012-04-26
CN102741260A (zh) 2012-10-17
AR078471A1 (es) 2011-11-09
TW201117814A (en) 2011-06-01
ZA201202328B (en) 2014-06-25
KR20120091166A (ko) 2012-08-17
ECSP12011756A (es) 2012-07-31
EA201270473A1 (ru) 2013-02-28
EP2483279A1 (en) 2012-08-08
MX2012003998A (es) 2012-04-20

Similar Documents

Publication Publication Date Title
PE20121534A1 (es) Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo
EA201490095A1 (ru) Новые производные майтанзиноида с пептидным линкером и их конъюгаты
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
CY1118777T1 (el) Μεθοδος για την παρασκευη ενωσεων χρησιμων ως αναστολεις του sglt2
EA201190021A1 (ru) Модуляторы toll-подобных рецепторов
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
EA201692215A1 (ru) Пирролбензодиазепины и конъюгаты направленного действия
TR201906416T4 (tr) Hiv inhibitörü bileşiklerin fosfonat analogları.
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
AR077055A1 (es) Derivados de benzimidazol como moduladores del canal trpm8
MX346291B (es) Reactivos de conjugación.
EA201200189A1 (ru) Фуразанобензимидазолы в качестве пролекарств для лечения опухолевых или аутоиммунных заболеваний
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
MX2018002242A (es) Compuestos de piperidinobenzodiazepina con actividad antiproliferativa.
CO2022004391A2 (es) Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4
MX2007007225A (es) Moduladores del receptor de la vitamina d.
CR11635A (es) Procedimiento de preparacion de combretastatina
AR104895A1 (es) Conjugados fluorescentes
GB2508567A (en) Light emitting composition and device
UY38906A (es) Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos
AR085770A1 (es) Compuestos antibioticos derivados de homoeritromicina y composiciones farmaceuticas
WO2012004419A3 (en) Modular construction of lipophospholipids
DOP2012000084A (es) Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo
EA201170509A1 (ru) Селективный модулятор рецепторов эстрогена
MX2009005891A (es) Nuevos derivados azabiciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FD Application declared void or lapsed